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Phosphorylation of Puma modulates its apoptotic
function by regulating protein stability
M Fricker*
,1,2, J O’Prey
1, AM Tolkovsky
2,3 and KM Ryan*
,1
Puma is a potent BH3-only protein that antagonises anti-apoptotic Bcl-2 proteins, promotes Bax/Bak activation and has an
essential role in multiple apoptotic models. Puma expression is normally kept very low, but can be induced by several
transcription factors including p53, p73, E2F1 and FOXO3a, whereby it can induce an apoptotic response. As Puma can to bind
and inactivate all anti-apoptotic members of the Bcl-2 family, its activity must be tightly controlled. We report here, for the ﬁrst
time, evidence that Puma is subject to post-translational control through phosphorylation. We show that Puma is
phosphorylated atmultiple sites,withthe major site ofphosphorylation being serine 10.Replacing serine 10with alanine causes
reduced Puma turnover and enhanced cell death. Interestingly, Puma turnover occurs through the proteasome, and substitution
of serine 10 causes elevated Puma levels independently of macroautophagy, Bcl-2 family member binding, caspase activity and
apoptotic death. We conclude, therefore, that phosphorylation of Puma at serine 10 promotes Puma turnover, represses Puma’s
cell death potential and promotes cell survival. Owing to the highly pro-apoptotic nature of Puma, these studies highlight an
important additional regulatory step in the determination of cellular life or death.
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The Bcl-2 family proteins have a crucial role in determining
cell fate by regulating the release of apoptogenic factors
from mitochondria through a process known as mitochondrial
outer membrane permeabilisation (MOMP).
1,2 Bcl-2 proteins
are divided into three sub-groups, on the basis of function and
the number of Bcl homology (BH) domains they possess.
1,2
The anti-apoptotic Bcl-2 family proteins, including Bcl-2,
Bcl-xL and Mcl-1, typically contain 3–4 BH domains, which
form a groove on the protein surface through which
pro-apoptotic Bcl-2 family proteins are bound. The pro-apoptotic
Bcl-2 family proteins are classiﬁed into two sub-groups,
the multi-domain proteins Bax and Bak, which contain BH
domains 1–3, and the BH3-only proteins, which, as the name
suggests, possess only the BH3 domain.
3 On receiving
an apoptotic stimulus, Bax and Bak homo-oligomerise on
the outer mitochondrial membrane, leading to MOMP and
subsequent caspase activation.
4 In non-apoptotic cells,
monomeric Bax and Bak are held in check through inhibitory
interactions with anti-apoptotic Bcl-2 proteins.
1,2,5 BH3-only
proteins contribute to the induction of apoptosis by compe-
ting with and displacing Bax and Bak from their inhibitory
interactions with anti-apoptotic Bcl-2 proteins.
3,6 In addition,
a subset of BH3-only proteins can directly interact with
and activate Bax/Bak.
7–9 In the absence of Bax and Bak,
the binding of BH3-only proteins to anti-apoptotic
Bcl-2-binding partners is insufﬁcient to induce apoptosis.
3,10
The BH3-only proteins are the largest subgroup of the
Bcl-2 family, comprising at least 12 members: Bad, Bim,
Bik/Nbk/Blk, Bid, Bmf, Puma, Noxa, Spike, BNIP3, Nix,
Hrk/DP5andBeclin-1.
3Giventheirintegralroleindetermining
cell fate, it is not surprising that the activity of BH3-only
proteins is stringently controlled, both through transcriptional
regulation and post-translational mechanisms such as
phosphorylation.
11 Puma was originally identiﬁed during
large-scale analysis for novel p53-inducible genes and
Bcl-2-interacting proteins.
12–14 Puma is an extremely
potent BH3-only protein, having the capacity to bind with high
afﬁnity toall knownanti-apoptotic Bcl-2 proteins.
15 Inaddition,
Puma may also directly interact with and activate Bax/Bak,
for example, through an interaction with the ﬁrst a-helix
of Bax.
7,8 In keeping with its highly pro-apoptotic nature,
Puma has been shown to have an essential role in the
induction of apoptosis in numerous in vitro and in vivo
systems and cell types including neurons, lymphocytes,
thymocytes, ﬁbroblasts and cardiomyocytes.
15,16 Puma
expression is regulated by transcription, and factors
regulating Puma transcription include p53, p73, E2F and
FOXO3a.
12,13,17–19 To date, however, no studies have
described the regulation of Puma activity by post-translational
means, despite numerous papers describing the post-
translational regulation of other BH3-only proteins including
Bad, Bim, Bmf and Bik.
20–24
Received 10.6.10; accepted 15.6.10; Edited by V De Laurenzi
1Tumour Cell Death Laboratory, Beatson Institute for Cancer Research, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK;
2Department of Biochemistry,
University of Cambridge, Cambridge CB2 1QW, UK and
3Cambridge Centre for Brain Repair, University of Cambridge, Cambridge CB2 OPY, UK
*Corresponding author: KM Ryan, Beatson Institute for Cancer Research, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK. Tel: þ44 141 330 3655;
Fax: þ44 014 194 26 521; E-mail: k.ryan@beatson.gla.ac.uk or M Fricker, Department of Biochemistry, University of Cambridge, Cambridge CB2 1QW, UK.
Tel: þ44 122 333 3701; Fax: þ44 122 333 3345; E-mail: mf309@cam.ac.uk
Keywords: Puma; phosphorylation; protein stability
Abbreviations: Baf, Boc-aspartyl-(O-methyl)-ﬂuoromethylketone; BH, Bcl homology; DKO MEF, Bax/Bak-null mouse embryo ﬁbroblast; MAPK, mitogen-activated
protein kinase; MOMP, mitochondrial outer membrane permeabilisation; 1D-TLC, one-dimensional thin-layer chromatography
Citation: Cell Death and Disease (2010) 1, e59; doi:10.1038/cddis.2010.38
& 2010 Macmillan Publishers Limited All rights reserved 2041-4889/10
www.nature.com/cddisHere, we provide the ﬁrst demonstration that Puma is
subject to post-translational regulation by phosphory-
lation. We ﬁnd that Puma is phosphorylated on several
evolutionarily conserved residues, with the principal site of
phosphorylationbeingSerine10.Aninabilitytophosphorylate
this site results in decreased Puma turnover, leading to
increased apoptotic death. Given the critical role of Puma
downstream of p53 and in multiple additional cell death
scenarios, these studies, therefore, highlight another poten-
tially critical control point in the cellular decision between
life and death.
Results
Exogenous Puma-a is phosphorylated in HeLa cells
on serine residues. To investigate whether Puma might
be phosphorylated, we transiently transfected HeLa cells
with constructs encoding N-terminally HA- or Flag-tagged
Puma for the purpose of labelling studies. In the absence
of caspase inhibitors, HeLa cells underwent apoptosis in
as little as 4h after transfection because of Puma expres-
sion (data not shown), leading to an insufﬁcient yield of
Puma protein for immunoprecipitation (IP). However, after
expression of Puma in HeLa cells for 12–18h in the presence
of the pan-caspase inhibitor Boc-aspartyl-(O-methyl)-ﬂuoro-
methylketone (BAF), both N-terminally HA- and Flag-tagged
Puma were successfully immunoprecipitated (Figure 1a
and c). To ascertain whether Puma was phosphorylated
in HeLa cells, at 12–16h after transfection, HeLa cells
were labelled with
32P-orthophosphate before lysis and IP.
Interestingly, IP of both N-terminal Flag- and HA-tagged
Puma resulted in the detection of an identical
32P-labelled
doublet, indicating that the phosphorylation of the proteins
was not in any way determined by either the HA- or FLAG
tag (Figure 1b and c). A non-apoptotic HA-tagged Puma
construct in which the BH3 domain was deleted (DBH3)
was also phospholabelled when transfected into HeLa cells
(Figure 1b). More radiolabel appeared to be incorporated into
this mutant, indicating not only that the BH3 domain is
dispensable for phosphorylation of Puma but also that
regions within the BH3 domain may potentially repress
phosphorylation elsewhere in the protein. Although this
speciﬁc possibility is yet to be determined, these results
clearly show that exogenous Puma is phosphorylated in
untreated HeLa cells in a BH3-domain-independent manner.
To determine the type(s) of residues in Puma that
are phosphorylated, phosphoamino acid analysis by one-
dimensional thin-layered chromatography (1D-TLC) was
used to identify whether serine, threonine or tyrosine residues
were phosphorylated in
32P-labelled cells expressing
HA-Puma-DBH3. Phosphoserine, phosphothreonine and
phosphotyrosine standards were separated by 1D-TLC and
detected by ninhydrin staining (Figure 1d and Supplementary
Figure 1). When
32P-labelled HA-Puma amino acids were
run on a TLC plate with phosphoamino acid standards,
a strong
32P signal was observed overlying the phospho-
serine standard, indicating that serine, but not threonine
or tyrosine residues, are phosphorylated in HA-Puma
(Figure 1d).
Serine 10 is the major site of phosphorylation in Puma-a.
Examination of the human Puma-a sequence shows
11 possible serines that could be sites of phosphorylation
(Figure 2a). Of these 11 serines, all but one are conserved
in the mouse and rat Puma sequences, the serine at position
75 of the human sequence being replaced with a proline in
both mouse and rat (Figure 2a). Cumulative serine-to-alanine
mutations within Puma were produced by a series of
site-directed mutagenesis reactions, in order to identify
phosphorylation sites by a process of elimination. Several
phosphorylation prediction programs (Netphos 2.0 (Technical
University of Denmark), Disphos (Temple University, PA,
USA) and Scansite (MIT, MA, USA)) were used to evaluate
which serine residues had a higher chance of being
phosphorylated, and these were grouped together for
mutation to alanine (serines 9, 10, 36, 96, 106 and 166),
whereas the other serines (33, 75, 83, 98 and 110) were
mutated in a separate series of mutagenesis reactions.
Mutation of serines 9, 10, 36, 96, 106 and 166 to alanine
completely prevented phosphorylation of Flag-Puma in HeLa
cells, eliminating both the upper and lower phosphate-labelled
bands (Figure 2b). In contrast, Puma in which serines 33, 75,
83, 98 and 110 had been mutated to alanines was
phosphorylated in an identical manner to wild-type (WT)
Puma. As expected, a construct in which all the serines within
Puma were mutated to alanines was not phosphorylated
(Figure 2b). These differences in phosphate labelling were not
due to differences in expression, as all four Puma constructs
used were efﬁciently immunoprecipitated when expressed in
HeLa cells (Figure 2c). These results conﬁrm the previous
observation from the phosphoamino acid analysis that Puma
is phosphorylated on serine residues, and show that serines
33, 75, 83, 98 and 110 are not targets for phosphorylation
within HeLa cells. Subsequent experiments focused on
revealing which of the serines 9, 10, 36, 96, 106 and 166 were
targets for phosphorylation. Further labelling reactions using
different combinations of serine-to-alanine mutations allowed
the sites of phosphorylation to be identiﬁed, which were
subsequently conﬁrmed using single-site mutants. Although
the S9A (serine 9 to alanine) mutant was phosphorylated
identically to WT-Puma, the S10A mutation completely
ablated the lower phosphorylated band (Figure 2d) without
affecting the upper band. Mutation of serines 96 and 106
speciﬁcally eliminated the upper phospho band (data not
shown), without reducing the phosphorylation of the lower
band. Although a S106A mutant also abrogated upper band
phosphorylation, we could not deﬁnitively rule out a role for
serine 96 in this phosphorylation event (Supplementary
Figure 2), and this requires further investigation.
Phosphorylation of Puma at serines 10, 96 and 106 also
occurs in MEF cells. To test whether Puma phosphory-
lation occurred in a different cell line and species, Bax/Bak
double knockout mouse embryonic ﬁbroblasts (DKO MEFs)
were chosen for use in a series of labelling experiments
similar to those performed in HeLa cells. DKO MEFs were
chosen as deletion of Bax/Bak is known to prevent Puma-
induced apoptosis,
25,26 facilitating expression of exogenous
Puma for IP. WT Puma was phosphorylated in DKO MEFs,
with upper and lower phosphate-labelled bands mimicking
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Cell Death and Diseasethe phosphorylation of Puma previously observed in HeLa
cells (Figure 2e). Furthermore, mutation of S10A prevented
32P-labelling of the lower band and mutation of serine 96
and 106 to alanine eliminated the upper band. As with HeLa
cells, mutation of all three sites was sufﬁcient to completely
prevent detectable phosphorylation of Puma in DKO MEFs
(Figure 2e). This result indicates that the phosphorylation of
Puma at serines 10, 96 and 106 is not a HeLa cell-speciﬁc
phenomenon. These data therefore show that Puma is
phosphorylated on several sites, the major site being serine
10 and the minor sites being serines 106 and/or 96, with
these phosphorylations appearing to occur independently
of one another. As the upper band was phosphorylated to
a much lesser extent than the lower band, we focused our
efforts on determining the functional effects of phosphory-
lation of the major site, that is, serine 10.
Increased induction of apoptosis by S10A Puma
compared with WT. To test whether mutation of serine 10
of Puma affected its apoptotic potency, expression constructs
for WT, S10A and the non-apoptotic BH3 mutant, DLRR,
were generated in the retroviral construct pBabe. This
construct was chosen as its expression is driven from the
relatively weak viral long-terminal repeat, thereby maximising
the chances of identifying functional consequences of phos-
phorylation at Serine 10. pBabe-WT and pBabe-S10A were
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Figure1 ExogenousPumaisphosphorylatedonserineresiduesinHeLacellsinaBH3domain-independentmanner(aandc)HeLacellsweretransfectedwithaplasmid
encoding HA-Puma (a) or Flag-Puma (c) and incubated in the presence of caspase inhibitor BAF for 16–20h before lysis. Overexpressed Puma was immunoprecipitated
using anti-HA antibody and protein A beads or anti-Flag beads. Immunoprecipitated Puma was detected using an anti-Puma N-terminus antibody. For analysis of
Puma phosphorylation, cells were incubated for 4h with
32P-orthophosphate before lysis. After SDS-PAGE, gels were stained with Coomassie to visualise protein and
dried.
32P-labelled HA-Puma (b, upper panel) and Flag-Puma (c, upper panel) were detected using a phosphorimager system. HA-Puma-WT was run in duplicate in panel b.
(d)
32P-labelled HA-Puma was transferred to PVDF membrane. The radioactive Puma band was excised from the membrane and amino acids were obtained by
acid hydrolysis.
32P-labelled amino acids were resuspended in 10ml milliQ water including phosphoamino acid standards and this sample was run on a 1D-TLC plate.
Phosphoamino acid standards were visualised by ninhydrin staining, and
32P-labelled amino acids were detected using a phoshorimager system
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Cell Death and Diseasetherefore co-transfected into HeLa cells with a vector
encoding farnesylated GFP (fGFP). fGFP retains a strong
ﬂuorescent signal during later phases of apoptosis, which,
along with evaluation of nuclear morphology by Hoechst
33342 staining, allowed quantiﬁcation of dying cells amongst
the transfected population. Of the GFP-positive population,
25% of those transfected with WT-Puma displayed apoptotic
nuclei, in comparison with 11.8% in cells transfected with
empty vector (Figure 3a and b). As expected, transfection
with the non-apoptotic BH3 mutant DLRR Puma did not
induce any death above that seen with the empty vector
(Figure 3a and b). Importantly, mutation of serine 10 to
alanine further enhanced the apoptosis associated with Puma
expression, with a further 9.2% of the transfected population
undergoing death compared with WT at the 20h time point
(Figure 3a and b, S10A¼35.0% death).
Non-phosphorylatable serine 10 mutants are stabilised
compared with WT serine 10. As phosphorylation of the
BH3 proteins Bim and Bad is known to modulate binding to
anti-apoptotic binding partners,
20–22 we tested whether muta-
tion of serine 10 altered the ability of Puma to bind Bcl-2,
Bcl-xL and Mcl-1, thereby explaining the difference in
apoptotic potential between this mutant and the WT protein.
Puma-S10A was, however, still able to bind these
anti-apoptotic members of the Bcl-2 family in keeping with the
position of serine 10 being far from the BH3 domain (Figure 4).
1   MARARQEGSSPEPVEGLARDGPRPFPLGRLVPSAVSCGLCEPGLAAAPAA
MARARQEGSSPEPVEGLARDSPRPFPLGRLMPSAVSCSLCEPGLPAAPAA
MARARQEGSSPEPVEGLARDSPRPFPLGRLMPSAVSCGLCEPGLPAAPAA
51  PTLLPAAYLCAPTAPPAVTAALGGSRWPGGPRSRPRGPRPDGPQPSLSLA
PALLPAAYLCAPTAPPAVTAALGGPRWPGGHRSRPRGPRPDGPQPSLSPA
PALLPAAYLCAPTAPPAVTAALGGPRWPGGHRSRPRGPRPDGPQPSLSPA
101 EQHLESPVPSAPGALAGGPTQAAPGVRGEEEQWAREIGAQLRRMADDLNA
QQHLESPVPSAPEALAGGPTQAAPGVRVEEEEWAREIGAQLRRMADDLNA
QQHLESPVPSAPEALAGGPTQAAPGVRVEEEEWAREIGAQLRRMADDLNA
151 QYERRRQEEQQRHRPSPWRVLYNLIMGLLPLPRGHRAPEMEPN
QYERRRQEEQHRHRPSPWRVMYNLFMGLLPLPRDPGAPEMEPN
QYERRRQEEQHRHRPSPWRVMYNLFMGLLPLPRDPGAPEMEPN
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Figure2 Serine10istheprinciplesiteofPumaphosphorylationinHeLacellsandMEFs.(a)AlignmentofPUMAproteinfromhuman(blacktext),mouse(greytext)andrat
(italics)–conservedserinesareindicatedbyblackarrowheadsandnon-conservedserinesbygreyarrowheads.HeLacells(bandd)orBax/Bakdoubleknockout(DKO)MEFs
(e)weretransfectedwithaplasmidencodingFlag-Pumacontainingserine-to-alaninemutationsatthesitesindicatedaboveeachlaneat12hbeforelabellingwith
32P-labelled
orthophosphate. Flag-Puma was captured using anti-Flag beads, separated by SDS-PAGE and visualised by coomassie staining.
32P-labelled proteins were detected using
a phosphorimager system. (c) Western blot detection of immunoprecipitated Puma mutants using an anti-Puma antibody
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Cell Death and DiseaseIt has also been reported that mitochondrial localisation has
an important role in the induction of death by Puma, although
this is not always the case.
26,27 Phosphorylation can also alter
the subcellular localisation of the BH3-only proteins Bim
and Bad, thus affecting their apoptotic potency.
20,24,28,29 To
examine whether mutation of serine 10 altered the subcellular
localisation of Puma, we performed immunoﬂuorescence on
HeLa cells and Bax/Bak DKO MEFs expressing Puma-WT or
Puma-S10A. In both HeLaand DKOMEF cells, WT andS10A
Puma co-localised to an equal extent with the mitochondrial
markers, mitotracker and TOM20 (Supplementary Figure 3).
We next analysed the expression levels of WT and S10A by
western blotting. This revealed that S10A was expressed at a
higher steady state level than WT Puma (Figure 5a). This
difference was not due to transfection efﬁciency or different
transcriptionratesfromthetwoplasmids,asequalamountsof
Puma mRNA could be detected by qPCR in the WT and
mutant Puma-expressing cells (Figure 5b).
Relatively little has been published regarding the regulation
of Puma protein stability. A recent paper from Callus et al.
30
showed, however, that after induction of MOMP and caspase
activation by expression of Puma from an inducible promoter,
Puma was degraded in a caspase-dependent manner.
Consequently, the authors showed that co-expression of
Bcl-2topreventMOMPorexpressionofPumainBax/Bak-null
cells that do not undergo MOMP (Wei et al.
10 and Supple-
mentaryFigure3)resultedinincreasedlevelsofPumaprotein
expression.
30 We therefore tested whether these factors
could affect the expression of WT Puma and the Puma-S10A
in our cell systems. When Puma was expressed in WT MEFs,
the presence of the pan-caspase inhibitor zVAD-fmk did not
result in any change in WT-Puma or S10A protein levels,
indicating that the difference in expression of Puma-WT and
Puma-S10A is not dependent on caspase activity (Figure 5c,
left panels). We also generated serine 10 mutants in
which three conserved amino acids within the BH3 domain
of Puma were mutated (DLRR), thus eliminating binding
to anti-apoptotic Bcl-2 proteins and rendering the protein
non-apoptotic. S10A-DLRR still showed higher steady
state levels than WT DLRR, conﬁrming that the increased
expression of S10A compared with WT protein was indepen-
dent of anti-apoptotic Bcl-2 protein binding, MOMP induction
and subsequent caspase activation (Figure 5d).
Puma has also recently been shown to induce degradation
of mitochondria by autophagy in a BH3-dependent, Bax/Bak-
dependent manner.
31 Given that Puma itself is a mitochond-
rially targeted protein, this raises the possibility that Puma
may trigger its own turnover by autophagic processes.
However, expression of Puma in MEFs lacking classical
macroautophagy due to genetic deletion of Atg5 did not affect
the relative expression of S10A compared with WT, when
compared with WT MEFs either in the absence or presence of
thepan-caspaseinhibitorzVAD-fmk.Theseﬁndingstherefore
rule out a role for macroautophagy in Puma turnover and the
selective modulation of Puma serine 10 mutant stability in our
cell systems (Figure 5c).
Turnover of the non-phosphorylatable S10A Puma is
delayed compared with the WT protein. As Puma was not
turned over by caspases or by autophagy in our cell systems,
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Figure 3 Non-phosphorylatable Puma mutant S10A induces apoptosis at a
greater rate than WT-Puma in HeLa cells. (a and b) HeLa cells were co-transfected
with the indicated Puma construct and a construct encoding farnesylated GFP.
At16h aftertransfection,cells wereﬁxedwith 4% PFAfor 20min,DNAwas stained
with Hoechst 33342 and then coverslips mounted for analysis by ﬂuorescence
microscopy (a). Cell death was quantiﬁed by examining the nuclear morphology
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Figure 4 Mutation of Puma serine 10 does not affect association of Puma
with Mcl-1, Bcl-2 or Bcl-xL. Cells expressing Myc-tagged Puma-WT or Puma-S10A
were immunoprecipitated with anti-Myc antibody and precipitated proteins
were analysed by western blotting with antibodies against: Mcl-1, Bcl-2, Bcl-Xl
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Cell Death and Diseasewe next tested whether Puma was targeted for degradation
at the proteasome. Cells expressing WT Puma were there-
fore treated with cycloheximide, and the rate of Puma decay
monitored either in the absence or presence of the protea-
some inhibitor, MG132. This assay revealed that degradation
of Puma was retarded in the presence of MG132, indicating
a role for the proteasome in Puma turnover and stability
(Figure 6a).
As these results indicate that Puma is actively turned over in
a proteasomal-dependent manner, we reasoned that the
increased amount of S10A protein observed may be caused
bydifferencesintherateofturnovercausedbyphosphorylation
of the WT protein. To test this possibility, we performed
35S pulse-chase analysis to measure the rate of degradation
of WT Puma and S10A in Bax/Bak DKO MEFs. Following a
1-h
35Spulseanda4-hchase,acleardecreaseintheamount
of
35S-labelled Puma-WT protein was observed, consistent
with it being degraded (Figure 6b). Although there was a small
decrease in
35S-labelled Puma-S10A during this period, this
decrease was markedly lower than the decrease observed
with the WT protein, with 56% of the S10A remaining relative
to t¼0 compared with 35% of the WT (Figure 6c). Thus,
the phosphorylation site at serine 10 has an important
role in determining the rate of turnover of Puma, with the
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Cell Death and Diseasenon-phosphorylatable S10A mutant being degraded at a
slower rate than the WT protein.
Discussion
To our knowledge, this is the ﬁrst report to show that the BH3-
only protein Puma is subject to post-translational modiﬁcation
by phosphorylation. We show that multiple serines are
phosphorylated on Puma with the major site being serine 10.
To date, previous studies have principally shown that Puma
is transcriptionally upregulated by pro-apoptotic factors such
as p53, p73, E2F and FOXO3a.
12,13,17–19 However, as not
all cells undergo a cell death response after up-regulation
of Puma by these transcription factors, this suggests that
other mechanisms may be at play to suppress the potent
death-inducing activity of Puma in cells. In this regard, it is
of interest that the potency of other BH3-only proteins, for
example, Bim and Bad, is reduced by phosphorylation
induced by survival signalling pathways.
20,22 This also seems
to be the case for Puma, as inhibition of phosphorylation at
serine 10 of Puma increases the pro-apoptotic potential of the
protein. Previous reports relating to phosphorylation of other
BH3-only proteins have shown that this can affect interaction
of the BH3-only protein with anti-apoptotic members of the
Bcl2 family. In the case of Puma, however, this seems not to
be the case, as equivalent levels of interaction were found
between anti-apoptotic members of the Bcl2 and either WT
Puma or a mutant of Puma in which serine 10 had been
mutated to alanine. In contrast, it was found that mutation of
serine 10 increased the half-life of the Puma, indicating that
phosphorylationatthisserinedestabilisestheprotein,thereby
keeping its death-inducing potential in check.
Although what we report here represents a deﬁnitive body
of work highlighting a new regulatory step in Puma function, a
number of questions are raised that are worthy of discussion.
First, it is important to consider which cellular signalling
pathways impinge on serine 10 to regulate Puma function.
In the case of Bad and Bim, classic survival pathways
are involved directly in their phosphorylation, such as Akt and
mitogen-activated protein kinase (MAPK) pathways, respec-
tively.
20,22 As serine 10 of Puma is immediately followed by
a proline, which indicates a potential MAPK phosphorylation
site, we considered that Puma may also be affected by MAPK
kinase signalling. However, treatment of cells with inhibitors
of p38, JNK and mitogen-activated protein kinase kinase
(the kinase that modulates the activity of the Erk1 and Erk2
MAPKs) had no effect on Puma stability or phosphorylation
(data notshown). In light of this, cellswere treated with a large
broader spectrum panel of kinase inhibitors, but no effects on
Puma stability were observed (data not shown). Therefore,
despite extensive efforts to identify a cellular signalling
pathway that affects Puma stability through serine 10
phosphorylation, the kinase(s) responsible for this effect
remain to be deﬁned. In addition, although beyond the scope
of the study presented here, it is also important to consider
how the other phosphorylation sites we have identiﬁed in
Puma, and the signalling pathways with which they connect,
may also affect Puma function. For instance, do these sites
work in concert with serine 10 to modulate Puma stability or
are they involved, as outlined above, in regulating BH3-only
function by controlling binding to anti-apoptotic Bcl2 family
proteins. Further studies in this area are undoubtedly
worthwhile and may also reveal further novel insights into
the regulation of Puma function.
In summary, the studies presented here highlight a novel
and potentially extremely important mechanism by which
cells can restrain one of the most potent death-inducing
proteins they contain. Through further investigation, our
ﬁndings also potentially open up new possibilities, whereby
we can modulate the death-inducing potential of Puma, either
positively or negatively, for therapeutic gain.
Materials and Methods
Cellcultureandconstructs. CelllineswereculturedinDulbecco’smodiﬁed
Eagle’s medium (DMEM) (Invitrogen, Paisley, UK) supplemented with 100U/ml
penicillin G, 100mg/ml streptomycin sulphate (Invitrogen) and 10% fetal bovine
serum (FBS) (Sigma, St Louis, MO, USA). Cells were maintained at 371Ci n5 %
CO2-balanced air. HeLa cells were obtained from ATCC (Manassas, VA, USA).
Bax/Bak DKO MEFs and Atg-5 knockout MEFs were kind gifts from Stanley
Korsmeyer (Dana-Farber Institute, Boston, MA, USA) and Noboru Mizushima
(Tokyo Medical and Dental University, Tokyo, Japan), respectively. DKO cell lines
stably expressing Puma and Puma mutants were generated as previously
described by retroviral infection of the pBabe-puro constructs outlined below.
32
HA-tagged Puma-a and ﬂag-tagged Puma-a constructs were generouslyprovidedby
Bert Vogelstein (HHMI, Johns Hopkins, Baltimore, MD, USA) and Karen Vousden
(Beatson Institute for Cancer Research, Glasgow, UK). To generate untagged,
N-terminally ﬂag-tagged or C-terminally Myc-tagged Puma constructs, Puma
was inserted into vectors pcDNA3.1, pcDNA3.1Myc/His and pBabe-puro by PCR
ampliﬁcation of ﬂag-tagged or untagged Puma sequences. All vector insertions
were veriﬁed by DNA sequencing.
Immunoprecipitation. HeLa cells or DKO MEFs were transfected using
Lipofectamine 2000 (Invitrogen) or Fugene 6 (Roche, Basel, Switzerland) following
the manufacturer’s instructions, and proteins were allowed to express for 16–20h.
HeLa cells were treated with pan-caspase inhibitor BAF (50mM) during this period
to prevent apoptotic death caused by Puma expression. Cells were lysed in 500ml
lysis buffer (50mM Tris-HCl (pH 7.5), 1% NP-40, 120mM NaCl, 1mM EDTA,
25mM NaF, 40mM b-glycerolphosphate, 1mM sodium orthovanadate, 1 
complete protease inhibitor cocktail (Roche)) and insoluble debris removed by
centrifugation at 10000r.p.m. at 41C for 10min. For HA-tag IP, 2mg of anti-HA
antibodywasadded(sc-805,SantaCruzBiotechnology,SantaCruz,CA,USA)and
incubated with the sample for 1h at 41C followed by a further addition of 50mlo fa
50% slurry of protein A sepharose beads (Sigma) and incubation overnight at 41C.
For Flag-tag IP, 30ml of anti-Flag M2 afﬁnity gel (Sigma) was added and lysates
incubated overnight at 41C as previously described.
33 For Myc-tag IP, 4mg of 4A6
monoclonal Myc antibody was added (Millipore, Billerica, MA, USA) and incubated
with the sample for 1h at 41C followed by a further addition of 50ml of a 50% slurry
of protein G sepharose beads (Sigma). Beads were washed four times in ice-cold
lysis buffer before being resuspended in 30mlo f1  gel-loading buffer (50mM
Tris-HCl (pH 6.8), 100mM DTT, 2% SDS, 10% glycerol and bromophenol blue).
Captured proteins were eluted by boiling for 5min and eluates loaded onto
appropriate SDS-PAGE gels.
Western blot analysis. For western blot analysis, 40mg protein lysate per
lane or protein eluate from IP were separated on 10–15% SDS-polyacrylamide gels
as previously described.
34 Proteins were transferred to 0.22mM pore nitrocellulose
membranes (GE Healthcare, Littlechalfort, UK). Primary antibodies were diluted in
TBS-T as follows: Puma anti-N-terminus (Prosci Inc, Poway, CA, USA; 1:1000),
Puma anti-C-terminus (Sigma; 1:500) and b-actin (Abcam, Cambridge, MA, USA;
1:5000). Signal was detected using an appropriate HRP-conjugated secondary
antibody and ECL reagents (GE Healthcare).
Metabolic labelling of cells with inorganic
32P. At 12–16h after trans-
fection, culture medium was replaced with phosphate-free DMEM (MP Biomedicals,
Solon, OH, USA) supplemented with 10% FBS and 0.5mCi
32P-labelled
orthophosphate (GE Healthcare). Cells were labelled for 4h in a humidiﬁed
atmosphere of 5% CO2. After labelling, cells were lysed and IPs performed as
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Cell Death and Diseasedescribedabove,beforeproteinswereseparatedbySDS-PAGE.Gelswerestainedfor
total protein in 50% methanol, 10% acetic acid (Sigma) and 0.1% Coomassie
R-250(Sigma) anddestainedin50%methanol.Oncedestained,gels weredriedusing
an ATTO RapiDry system (ATTO, Tokyo, Japan), and
32P-labelled proteins were then
detected using a phosphorimager system (Molecular Dynamics, Sevenoaks, UK).
Phosphoamino acid analysis. For the purposes of phosphoamino acid
analysis,
32P-labelled proteins were separated by SDS-PAGE as described above
and electroblotted onto a PVDF (Immobilon P, Millipore) membrane. Total protein
was visualised by staining with 0.1% India Ink in PBS and 0.3% Tween.
Radiolabelled proteins were detected using the phosphorimager as before, and hot
protein bands were excised from the PVDF membrane using a sterile scalpel. After
acid hydrolysis in 6M HCl at 1101C for 1h, the sample was cooled and the liquid
hydrolysate was transferred to a fresh tube and dried using a SpeedVac (Thermo
Fisher Scientiﬁc, Waltham, MA, USA). Sample was redissolved in 10ml milliQ H2O
andspottedontoaplastic-backedcelluloseTLCplate.Phosphoserine,-threonineor
-tyrosine standards (10mg) were run alongside samples using butanol/acetic acid/
ethanol/H2O (1:1:1:1) as the mobile phase. Phosphoamino acid standards were
visualised by staining with 0.25% (w/v) ninhydrin in acetone and radiolabelled
phosphoamino acids were detected using the phosphorimager system.
Site-directed mutagenesis. The13 serineresiduesin humanPuma-a were
replaced with alanine residues using the Quikchange multi-site-directed muta-
genesis kit (Agilent Technologies, Santa Clara, CA, USA) according to the
manufacturer’s instructions. Mutagenic primers were designed to anneal to the
same strand of template DNA, have a minimum GC content of 40%, terminate with
at least one G or C, be between 25 and 45 base pairs long and have a melting
temperature of over 751C as calculated using the tools available in the website
http://www.stratagene.com.
qPCR analysis. Total RNA was extracted from cells using the Qiagen RNeasy
Mini Kit (Qiagen, Hilden, Germany) following the manufacturer’s instructions. RNA was
eluted in RNase-free water and stored at  801C. Total RNA was quantiﬁed by
absorbance at 260nm (Nanodrop Technologies, Wilmington, DE, USA), and 0.5mgo f
RNA from each sample was used for cDNA synthesis using the DyNAmo kit (Thermo
Fisher Scientiﬁc). Gene-speciﬁc oligonucleotides were obtained from Qiagen, and SYBR
Green was used to detect Taq-ampliﬁed products. qPCR reactions were carried out as
previously described.
35 All signals were normalised against 18S rRNA.
Quantiﬁcation of cell death. HeLa cells plated on glass coverslips were
transfected with a 1:1 ratio of Puma and fGFP expression plasmids. At 16h post-
transfection, cells were ﬁxed in 3% PFA and nuclei-stained using Hoechst 33342
before mounting on slides. GFP-positive cells were counted and cell death in the GFP-
positive population evaluated by nuclear and cellular morphology. As expected, cell
death was not induced by amutant form of Pumalacking afunctional BH3domain and
was inhibited by the pan-caspase inhibitor zVAD-fmk (not shown).
Immunocytochemistry. Cells were ﬁxed in 3% paraformaldehyde for 20min
at room temperature and coverslips were then washed three times in ice-cold PBS.
Cells were permeabilised for 30min at room temperature in PBS and 0.3% Triton
X-100 (PBSTX) (VWR, West Chester, PA, USA). Coverslips were incubated with
primary antibodies overnight at 41C. Primary antibodies were diluted as follows:
Pumaanti-N-terminus(ProsciInc;1:500),Tom20(BDBiosciences,SanHose,CA,
USA,no.612278;1:1000). AfterfourwashesinPBSTX,coverslipswereincubated
with appropriate ﬂuorescence-conjugated secondary antibodies at room
temperature for 1h. Cells were washed a further two times with PBS before a
brief incubation with 5mg/ml Hoechst 33342 (Sigma) and further washes in PBS.
Coverslips were mounted using Fluoromount-G (Southern Biotech, Birmingham,
AL, USA) and analysed by confocal microscopy (IX70 connected to UltaVIEW, LCI
confocal imaging system, Perkin Elmer, Waltham, MA, USA).
Metabolic labelling of cells with
35S methionine/cysteine for
pulse-chase analysis. At 16h after transfection with myc-tagged Puma
constructs, DKO MEFs were placed in DMEM lacking methionine and cysteine
supplemented with 10% dialysed FBS for 1h before addition of 50mCi of
35S-labelled methionine/cysteine (PerkinElmer). After a 60min pulse, cells were
washed 3 times in PBS and then chased in DMEM containing excess cold
methionineandcysteine(2mM)for thetimeperiodsindicated.Cellswerelysed and
myc-tagged Puma was captured by IP as described above. Immunoprecipitated
proteinswereseparatedbySDS-PAGE,transferredtonitrocellulosemembranesfor
detection of Puma by western blot followed by exposure to a phosphorimager
screen in order to detect the amount of
35S signal.
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